Drug details
Belrapzo (bendamustine hydrochloride injection)
type of Antineoplastics, Alkylating
Belrapzo (bendamustine hydrochloride injection) is an alkylating drug indicated for treatment of patients with chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
This drug may have the following side effects:
- hives,
- difficulty breathing,
- swelling of your face, lips, tongue, or throat,
- loss of appetite,
- vomiting,
- diarrhea,
- fever,
- swollen glands,
- easy bruising,
- unusual bleeding,
- pale skin,
- lightheadedness,
- shortness of breath,
- cold hands and feet,
- confusion,
- chills,
- tiredness,
- muscle aches,
- weakness,
- sore throat,
- skin pain,
- mouth sores,
- muscle cramps,
- right-sided upper stomach pain,
- skin sores,
- burning in your eyes,
- feeling unwell,
- severe weakness,
- yellowing of your skin or eyes (jaundice),
- red or purple skin rash that spreads and causes blistering and peeling,
- itching during or shortly after the injection,
- pain, swelling, redness, skin changes, or signs of infection where the medicine was injected,
- severe ongoing nausea,
- fast or slow heart rate,
- decreased urination, and
- tingling in your hands and feet or around your mouth
The following drugs are related to Belrapzo, either as a replacement or used together:
- Arzerra (ofatumumab injection)
- Asparlas (calaspargase pegol-mknl injection)
- Bendeka (bendamustine hydrochloride injection)
- Bosulif (bosutinib tablets)
- Copiktra (duvelisi capsules)
- Elzonris (tagraxofusp-erzs injection)
- Gazyva (obinutuzumab injection)
- Imbruvica (ibrutinib capsules)
- Kymriah (tisagenlecleucel suspension for intravenous infusion)
- Pepaxto (melphalan flufenamide for injection for iv use)
- Monjuvi (tafasitamab-cxix injection)
- Oncaspar (pegaspargase)